Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches.
Publication
, Journal Article
Strickler, JH; Wu, C; Bekaii-Saab, T
Published in: Cancer Treat Rev
November 2017
Oncogenic mutations in B-type Raf kinase (BRAF) occur in 7-10% of metastatic colorectal cancers (mCRC). Despite recent improvements in survival in the general population of patients with mCRC, patients with BRAF-mutant mCRC continue to have poor response to most systemic therapies, and prognosis remains poor. There is a substantial unmet need for novel therapeutic strategies to treat patients with BRAF-mutant mCRC. This review outlines the epidemiology, molecular pathogenesis, prognosis, and mechanisms of treatment resistance of BRAF-mutated CRC. Additionally, this review highlights novel therapeutic strategies aimed at enhancing response and improving outcomes.
Duke Scholars
Published In
Cancer Treat Rev
DOI
EISSN
1532-1967
Publication Date
November 2017
Volume
60
Start / End Page
109 / 119
Location
Netherlands
Related Subject Headings
- Proto-Oncogene Proteins B-raf
- Oncology & Carcinogenesis
- Neoplasm Metastasis
- Molecular Targeted Therapy
- Humans
- Colorectal Neoplasms
- Biomarkers, Tumor
- Antineoplastic Agents
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Strickler, J. H., Wu, C., & Bekaii-Saab, T. (2017). Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches. Cancer Treat Rev, 60, 109–119. https://doi.org/10.1016/j.ctrv.2017.08.006
Strickler, John H., Christina Wu, and Tanios Bekaii-Saab. “Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches.” Cancer Treat Rev 60 (November 2017): 109–19. https://doi.org/10.1016/j.ctrv.2017.08.006.
Strickler JH, Wu C, Bekaii-Saab T. Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches. Cancer Treat Rev. 2017 Nov;60:109–19.
Strickler, John H., et al. “Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches.” Cancer Treat Rev, vol. 60, Nov. 2017, pp. 109–19. Pubmed, doi:10.1016/j.ctrv.2017.08.006.
Strickler JH, Wu C, Bekaii-Saab T. Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches. Cancer Treat Rev. 2017 Nov;60:109–119.
Published In
Cancer Treat Rev
DOI
EISSN
1532-1967
Publication Date
November 2017
Volume
60
Start / End Page
109 / 119
Location
Netherlands
Related Subject Headings
- Proto-Oncogene Proteins B-raf
- Oncology & Carcinogenesis
- Neoplasm Metastasis
- Molecular Targeted Therapy
- Humans
- Colorectal Neoplasms
- Biomarkers, Tumor
- Antineoplastic Agents
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis